24-HOUR BLOOD-PRESSURE DURING ANTIHYPERTE NSIVE THERAPY WITH RAMIPRILIN RENAL-TRANSPLANT RECIPIENTS

The efficacy of the new ACE-inhibitor ramipril in the treatment of hyp ertension is well established, but there is no experience of the use o f ramipril in hypertensive renal recipients. In the present prospectiv e study the efficacy and safety of the antihypertensive therapy with r amipril (2,5 mg, 5 mg or 10 mg ramipril) were examined in 10 untreated hypertensive renal transplant recipients with stable transplant funct ion (age 41,7 +/- 8,3 years, 8,4 +/- 3,7 months after transplantation) . 24-hour blood pressure monitoring (SpaceLabs 90207) was performed be fore, and 2 and 6 weeks after ramipril therapy. 24-hour blood pressure was 155,8 +/- 7,1/96,1 +/- 3,0 mmHg before the ramipril therapy and d ropped to 147,6 +/- 3,73/87,5 +/- 3,1 mmHg after 2 weeks and to 140,6 +/- 5,4/84,5 +/- 2,4 mmHg after 6 weeks of therapy. The serum creatini ne decreased from 2,17 +/- 0,67 mg to 1,92 +/- 0,56 mg/dl after 2 week s (n.s.) and to 1,63 +/- 0,51 mg/dl after 6 weeks (n.s.). The ciclospo rine A level remained unchanged. No anemia was induced by the therapy with ramipril. The results show that ramipril is a safe and efficient drug to treat hypertension in renal transplant recipients.